Guildford, UK, 19 November 2013: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will be announcing its interim results for the six months ended 30 September 2013, on Monday 2 December 2013.

A meeting for analysts will be held at 10.00am on the morning of the results of the announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results:

A recording of the webcast will be made available on ReNeuron’s and Buchanan’s websites, and


ReNeuron                                                                +44 (0) 1483 302560

Michael Hunt, Chief Executive Officer

Dr John Sinden, Chief Scientific Officer

Richard Moulson, Interim CFO

Buchanan                                                                +44 (0) 20 7466 5000

Mark Court, Fiona Henson, Sophie Cowles

Cenkos Securities                                                     +44 (0) 20 7397 8900

Stephen Keys, Christopher Golden (NOMAD and Broker)

Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. 

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research. The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at